PA21 + Sevelamer hydrochloride

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis

Conditions

Hemodialysis, Hyperphosphatemia

Trial Timeline

Apr 23, 2013 → Dec 10, 2013

About PA21 + Sevelamer hydrochloride

PA21 + Sevelamer hydrochloride is a phase 3 stage product being developed by Kissei Pharmaceutical for Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01850602. Target conditions include Hemodialysis, Hyperphosphatemia.

What happened to similar drugs?

2 of 15 similar drugs in Hemodialysis were approved

Approved (2) Terminated (0) Active (13)
DoravirineMerckApproved
EnoxaparineSanofiApproved
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄roxadustat + Darbepoetin alfaAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01850602Phase 3Completed

Competing Products

20 competing products in Hemodialysis

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP7991Astellas PharmaPhase 1
29
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP1585Astellas PharmaPhase 2
35
Kiklin capsulesAstellas PharmaPre-clinical
26
DoravirineMerckApproved
43
BPS804 + PlaceboNovartisPhase 2
27
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PA21Kissei PharmaceuticalPhase 3
40
[¹⁴C]EtelcalcetideAmgenPhase 1
29
Epoetin HospiraPfizerPhase 3
40
Epoetin HospiraPfizerPhase 3
40
sodium thiosulfateSanofiPre-clinical
26
EnoxaparineSanofiApproved
43
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
36